MUJI 0.5 mm Gel Ink Pen Set – Black (Pack of 6)

Product Information

If you can’t turn the dose selector on your Ozempic pen, or there is no fluid in the pen window, then your pen is empty. The maximum dose of Ozempic is 2 mg once a week. Administer the injection once weekly, on the same day each week, at any time of the day, with or without meals.

Patients with low body weight may experience more gastrointestinal side effects when treated with semaglutide. If you have severe and on-going pain in the stomach area see a doctor straight away as this could be a sign of inflamed pancreas (acute pancreatitis).

Which Is More Common: 0.5 Or 0.7?

The efficacy and safety of semaglutide 0.5 mg and 1 mg once weekly were evaluated in six randomised controlled phase 3a trials that included 7 215 patients with type 2 diabetes mellitus (4 107 treated with semaglutide). Five trials (SUSTAIN 1–5) had the glycaemic efficacy assessment as the primary objective, while one trial (SUSTAIN 6) had cardiovascular outcome as the primary objective. No dose adjustment is required based on age. Therapeutic experience in patients ≥75 years of age is limited (see section 5.2). No dose adjustment is required for patients with hepatic impairment. Experience with the use of Semaglutide in patients with severe hepatic impairment is limited. Caution should be exercised when treating these patients with semaglutide (see section 5.2). along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus.

Semaglutide lowered high blood glucose concentrations by stimulating insulin secretion and lowering glucagon secretion in a glucose dependent manner. With semaglutide, the insulin secretion rate in patients with type 2 diabetes was comparable to that of healthy subjects. Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions. This should be considered when treating patients, with impaired renal function as nausea, vomiting, and diarrhoea may cause dehydration which could cause a deterioration of renal function (see section 4.8). The needle is covered by two caps. You must remove both caps. If you forget to remove both caps you will not inject any wegovy. Non-lethal thyroid C-cell tumours observed in rodents are a class effect for GLP-1 receptor agonists. In 2-year carcinogenicity studies in rats and mice, semaglutide caused thyroid C-cell tumours at clinically relevant exposures. No other treatment-related tumours were observed. The rodent C-cell tumours are caused by a non-genotoxic, specific GLP-1 receptor mediated mechanism to which rodents are particularly sensitive. The relevance for humans is considered to be low, but cannot be completely excluded.

In developmental toxicity studies in rabbits and cynomolgus monkeys, increased pregnancy loss and slightly increased incidence of foetal abnormalities were observed at clinically relevant exposures. The findings coincided with marked maternal body weight loss of up to 16%. Whether these effects are related to the decreased maternal food consumption as a direct GLP-1 effect is unknown. The effect of semaglutide on cardiac repolarization was tested in a thorough QTc trial. Semaglutide did not prolong QTc intervals at dose levels up to 1.5 mg at steady state.

Studies in animals have shown reproductive toxicity (see section 5.3). There are limited data from the use of semaglutide in pregnant women. Therefore, semaglutide should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy occurs, semaglutide should be discontinued. Semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life (see section 5.2). Body weight has an effect on the exposure of semaglutide. Higher body weight results in lower exposure; a 20% difference in body weight between individuals will result in an approximate 16% difference in exposure. Semaglutide doses of 0.5 mg and 1 mg provide adequate systemic exposure over a body weight range of 40–198 kg. Semaglutide compared to placebo lowered fasting triglyceride and very low density lipoproteins (VLDL) cholesterol concentrations by 12% and 21%, respectively. The postprandial triglyceride and VLDL cholesterol response to a high fat meal was reduced by >40%. Never use a bent or damaged needle. For more information about needle handling, see ‘About your needles’ below these instructions.

Official answer

For example, let’s say you use the Ozempic pen that delivers the 0.25 or 0.5 mg doses (total strength per pen is 2 mg per 3 mL). This pen only delivers doses in 0.25 mg or 0.5 mg strengths increments No episodes of severe hypoglycaemia were observed when semaglutide was used as monotherapy. Severe hypoglycaemia was primarily observed when semaglutide was used with a sulfonylurea (1.2% of subjects, 0.03 events/patient year) or insulin (1.5% of subjects, 0.02 events/patient year). Few episodes (0.1% of subjects, 0.001 events/patient year) were observed with semaglutide in combination with oral antidiabetics other than sulfonylureas. Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. The efficacy and safety of semaglutide 2 mg once weekly was evaluated in a phase 3b trial (SUSTAIN FORTE) including 961 patients.

If you use the 0.5 mg, 1 mg or 2 mg maintenance dose per week, your pen will hold 4 doses and last for one month. The safety and efficacy of semaglutide in children and adolescents below 18 years have not yet been established. No data are available. In a 104-week double-blind trial (SUSTAIN 6), 3 297 patients with type 2 diabetes mellitus at high cardiovascular risk were randomised to either semaglutide 0.5 mg once weekly, semaglutide 1 mg once weekly or corresponding placebo in addition to standard-of-care hereafter followed for 2 years. In total 98% of the patients completed the trial and the vital status was known at the end of the trial for 99.6% of the patients.Once your pen is empty, dispose of it right away in an FDA-cleared sharps disposal container or other household container (such as an upright, heavy-duty, leak-resistant plastic container with a tight-fitting, puncture-resistant lid and labeled to warn of hazardous waste). Is Ozempic available in a starter-kit? The primary endpoint was time from randomisation to first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. Your doctor, nurse or pharmacist will show you how to use Ozempic the first time. Ozempic is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Do not inject Ozempic into a muscle (intramuscularly) or vein (intravenously).